| payload |
{"created_at":"2026-04-18T03:05:05.644 {"created_at":"2026-04-18T03:05:05.644967+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:13825af01a2945b7","evidence_event_ids":["evt_bb59d8f988d1"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-002373.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-002373.txt","company":"VOLITIONRX LTD","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-002373.txt","article_chars":3919,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_ced9feae28103bdc","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-002373.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:21:06.602504+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"vnrx_8k.htm","final_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-002373.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-002373.txt","source_event_id":"evt_bb59d8f988d1","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"2fd015a023662161","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-17","2026-04-18","2026-04-01","2026-03-31","2026-04-28","2026-01-15","2025-05-20"],"entities":[{"asset_class":"equity","name":"VolitionRx Limited","relevance":"primary","symbol":"","type":"issuer"},{"asset_class":"other","name":"Lind Global Asset Management XII LLC","relevance":"secondary","symbol":"","type":"counterparty"}],"event_type":"listing","information_gaps":["The filing\u2019s SEC \u201cItem\u201d number is stated as Item 8.01 (Other Events), but no additional financial guidance or quantitative financial impact is provided in the provided text.","The specific approved range of reverse split ratios from the April 1, 2026 disclosure is not included in the provided text.","No ticker symbol for VolitionRx Limited is provided in the text, so a standardized tradable symbol cannot be populated."],"key_facts":["The company previously disclosed shareholder approval (under Item 5.07 of an 8-K filed April 1, 2026) for the board to exercise discretion to amend the Second Amended and Restated Certificate of Incorporation to effect a reverse stock split with a ratio within an approved range.","The board approved the reverse stock split at a ratio of one-for-twenty (1-for-20) (the \u201cSplit Ratio\u201d).","The reverse stock split is being effected in consideration of terms of documents executed in connection with financings with Lind Global Asset Management XII LLC consummated on May 20, 2025 and January 15, 2026.","The reverse stock split is expected to become effective at 12:01 a.m. ET on April 28, 2026 (the \u201cEffective Date\u201d).","Shares are expected to begin trading on a split-adjusted basis at market open.","As of the Effective Date, every 20 shares of common stock will be automatically converted into one share of common stock.","No fractional shares will be issued; holders entitled to fractional shares will receive one whole share in lieu of fractional shares.","Outstanding warrants, options, equity incentive awards, and other outstanding equity securities and instruments will be rounded up to the next whole share or, if applicable, cash will be paid in lieu of fractional shares per their terms.","Proportionate adjustments will be made (per the Split Ratio) to: (i) outstanding equity incentive awards under the 2015 Stock Incentive Plan and 2024 Stock Incentive Plan, (ii) outstanding warrants and convertible notes, (iii) shares of common stock available for future issuance under the 2024 Stock Incentive Plan, and (iv) other outstanding equity securities and instruments."],"numeric_claims":[{"label":"Reverse stock split ratio","value":"1-for-20"},{"label":"Effective time","value":"12:01 a.m. ET"},{"label":"Effective date","value":"2026-04-28"},{"label":"Conversion rule","value":"20 shares -> 1 share"},{"label":"Rounding rule","value":"fractional shares rounded up to next whole share; cash may be paid in lieu per instrument terms"}],"primary_claim":"The board approved a reverse stock split of VolitionRx Limited\u2019s common stock at a ratio of one-for-twenty (1-for-20), expected to become effective at 12:01 a.m. ET on April 28, 2026.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"VolitionRx Limited filed an 8-K to announce that its board approved and the company is effecting a 1-for-20 reverse stock split of its common stock. The split is expected to become effective April 28, 2026 and will adjust outstanding equity awards and instruments proportionately.","topics":["reverse stock split","common stock","share conversion","equity award adjustments","warrants and convertible notes","SEC 8-K","corporate actions"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 VOLITIONRX LTD \u00b7 Filed 20260417","ticker":"VNRX","tickers":["VNRX"],"title":"VNRX filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/93314/0001477932-26-002373.txt"}}... |